

Global Medications for Prurigo Nodularis Market Growth 2026-2032

<https://marketpublishers.com/r/G31BFE8655AFEN.html>

Date: April 2026

Pages: 117

Price: US\$ 3,660.00 (Single User License)

ID: G31BFE8655AFEN

Abstracts

The global Medications for Prurigo Nodularis market size is predicted to grow from US\$ million in 2025 to US\$ million in 2032; it is expected to grow at a CAGR of % from 2026 to 2032.

Prurigo nodularis is a type of disease associated to the skin which causes itchy lumps on the skin. The itching turns to be so serious that it leads to scratches and bleeding, mainly categorized as the rare disease. The treatment for these rare disease is termed as prurigo nodularis treatment. It can get adverse when comes in contact with clothes and the common symptom associated with this disease is itchy nodules on the skin. It can be found on outer arms, legs and shoulders.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LP Information, Inc. (LPI) ' newest research report, the 'Medications for Prurigo Nodularis Industry Forecast' looks at past sales and reviews total world Medications for Prurigo Nodularis sales in 2025, providing a comprehensive analysis by region and market sector of projected Medications for Prurigo Nodularis sales for 2026 through 2032. With Medications for Prurigo Nodularis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Medications for Prurigo Nodularis industry.

This Insight Report provides a comprehensive analysis of the global Medications for Prurigo Nodularis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Medications for Prurigo Nodularis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Medications for Prurigo Nodularis market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Medications for Prurigo Nodularis and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Medications for Prurigo Nodularis.

This report presents a comprehensive overview, market shares, and growth opportunities of Medications for Prurigo Nodularis market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Antihistamines

Capsaicin Cream

Corticosteroids

Emollients

Other

Segmentation by Application:

Hospitals

Specialty Clinics

Homecare

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Johnson & Johnson Services, Inc

Teva Pharmaceutical Industries Ltd

Pfizer Inc

Hikma Pharmaceuticals PLC

Takeda Pharmaceutical Company Limited

Bayer AG

Merck & Co., Inc

Sanofi

GSK plc

BRISTOL-MYERS SQUIBB COMPANY

GALDERMA LABORATORIES, L.P

Mayne Pharma Group Limited

VYNE Therapeutics Inc

Trevi Therapeutics

Key Questions Addressed in this Report

What is the 10-year outlook for the global Medications for Prurigo Nodularis market?

What factors are driving Medications for Prurigo Nodularis market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Medications for Prurigo Nodularis market opportunities vary by end market size?

How does Medications for Prurigo Nodularis break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Medications for Prurigo Nodularis Annual Sales 2021-2032
- 2.1.2 World Current & Future Analysis for Medications for Prurigo Nodularis by Geographic Region, 2021, 2025 & 2032
- 2.1.3 World Current & Future Analysis for Medications for Prurigo Nodularis by Country/Region, 2021, 2025 & 2032

2.2 Medications for Prurigo Nodularis Segment by Type

- 2.2.1 Antihistamines
- 2.2.2 Capsaicin Cream
- 2.2.3 Corticosteroids
- 2.2.4 Emollients
- 2.2.5 Other
- 2.2.6 Medications for Prurigo Nodularis Sales by Type
 - 2.2.6.1 Global Medications for Prurigo Nodularis Sales Market Share by Type (2021-2026)
 - 2.2.6.2 Global Medications for Prurigo Nodularis Revenue and Market Share by Type (2021-2026)
 - 2.2.6.3 Global Medications for Prurigo Nodularis Sale Price by Type (2021-2026)

2.3 Medications for Prurigo Nodularis Segment by Application

- 2.3.1 Hospitals
- 2.3.2 Specialty Clinics
- 2.3.3 Homecare
- 2.3.4 Other
- 2.3.5 Medications for Prurigo Nodularis Sales by Application

2.3.5.1 Global Medications for Prurigo Nodularis Sale Market Share by Application (2021-2026)

2.3.5.2 Global Medications for Prurigo Nodularis Revenue and Market Share by Application (2021-2026)

2.3.5.3 Global Medications for Prurigo Nodularis Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Medications for Prurigo Nodularis Breakdown Data by Company

3.1.1 Global Medications for Prurigo Nodularis Annual Sales by Company (2021-2026)

3.1.2 Global Medications for Prurigo Nodularis Sales Market Share by Company (2021-2026)

3.2 Global Medications for Prurigo Nodularis Annual Revenue by Company (2021-2026)

3.2.1 Global Medications for Prurigo Nodularis Revenue by Company (2021-2026)

3.2.2 Global Medications for Prurigo Nodularis Revenue Market Share by Company (2021-2026)

3.3 Global Medications for Prurigo Nodularis Sale Price by Company

3.4 Key Manufacturers Medications for Prurigo Nodularis Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Medications for Prurigo Nodularis Product Location Distribution

3.4.2 Players Medications for Prurigo Nodularis Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR MEDICATIONS FOR PRURIGO NODULARIS BY GEOGRAPHIC REGION

4.1 World Historic Medications for Prurigo Nodularis Market Size by Geographic Region (2021-2026)

4.1.1 Global Medications for Prurigo Nodularis Annual Sales by Geographic Region (2021-2026)

4.1.2 Global Medications for Prurigo Nodularis Annual Revenue by Geographic Region (2021-2026)

4.2 World Historic Medications for Prurigo Nodularis Market Size by Country/Region

(2021-2026)

4.2.1 Global Medications for Prurigo Nodularis Annual Sales by Country/Region

(2021-2026)

4.2.2 Global Medications for Prurigo Nodularis Annual Revenue by Country/Region

(2021-2026)

4.3 Americas Medications for Prurigo Nodularis Sales Growth

4.4 APAC Medications for Prurigo Nodularis Sales Growth

4.5 Europe Medications for Prurigo Nodularis Sales Growth

4.6 Middle East & Africa Medications for Prurigo Nodularis Sales Growth

5 AMERICAS

5.1 Americas Medications for Prurigo Nodularis Sales by Country

5.1.1 Americas Medications for Prurigo Nodularis Sales by Country (2021-2026)

5.1.2 Americas Medications for Prurigo Nodularis Revenue by Country (2021-2026)

5.2 Americas Medications for Prurigo Nodularis Sales by Type (2021-2026)

5.3 Americas Medications for Prurigo Nodularis Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Medications for Prurigo Nodularis Sales by Region

6.1.1 APAC Medications for Prurigo Nodularis Sales by Region (2021-2026)

6.1.2 APAC Medications for Prurigo Nodularis Revenue by Region (2021-2026)

6.2 APAC Medications for Prurigo Nodularis Sales by Type (2021-2026)

6.3 APAC Medications for Prurigo Nodularis Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Medications for Prurigo Nodularis by Country

7.1.1 Europe Medications for Prurigo Nodularis Sales by Country (2021-2026)

7.1.2 Europe Medications for Prurigo Nodularis Revenue by Country (2021-2026)

7.2 Europe Medications for Prurigo Nodularis Sales by Type (2021-2026)

7.3 Europe Medications for Prurigo Nodularis Sales by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Medications for Prurigo Nodularis by Country

8.1.1 Middle East & Africa Medications for Prurigo Nodularis Sales by Country (2021-2026)

8.1.2 Middle East & Africa Medications for Prurigo Nodularis Revenue by Country (2021-2026)

8.2 Middle East & Africa Medications for Prurigo Nodularis Sales by Type (2021-2026)

8.3 Middle East & Africa Medications for Prurigo Nodularis Sales by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Medications for Prurigo Nodularis

10.3 Manufacturing Process Analysis of Medications for Prurigo Nodularis

10.4 Industry Chain Structure of Medications for Prurigo Nodularis

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Medications for Prurigo Nodularis Distributors

11.3 Medications for Prurigo Nodularis Customer

12 WORLD FORECAST REVIEW FOR MEDICATIONS FOR PRURIGO NODULARIS BY GEOGRAPHIC REGION

12.1 Global Medications for Prurigo Nodularis Market Size Forecast by Region

12.1.1 Global Medications for Prurigo Nodularis Forecast by Region (2027-2032)

12.1.2 Global Medications for Prurigo Nodularis Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global Medications for Prurigo Nodularis Forecast by Type (2027-2032)

12.7 Global Medications for Prurigo Nodularis Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Johnson & Johnson Services, Inc

13.1.1 Johnson & Johnson Services, Inc Company Information

13.1.2 Johnson & Johnson Services, Inc Medications for Prurigo Nodularis Product Portfolios and Specifications

13.1.3 Johnson & Johnson Services, Inc Medications for Prurigo Nodularis Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 Johnson & Johnson Services, Inc Main Business Overview

13.1.5 Johnson & Johnson Services, Inc Latest Developments

13.2 Teva Pharmaceutical Industries Ltd

13.2.1 Teva Pharmaceutical Industries Ltd Company Information

13.2.2 Teva Pharmaceutical Industries Ltd Medications for Prurigo Nodularis Product Portfolios and Specifications

13.2.3 Teva Pharmaceutical Industries Ltd Medications for Prurigo Nodularis Sales, Revenue, Price and Gross Margin (2021-2026)

- 13.2.4 Teva Pharmaceutical Industries Ltd Main Business Overview
- 13.2.5 Teva Pharmaceutical Industries Ltd Latest Developments
- 13.3 Pfizer Inc
 - 13.3.1 Pfizer Inc Company Information
 - 13.3.2 Pfizer Inc Medications for Prurigo Nodularis Product Portfolios and Specifications
 - 13.3.3 Pfizer Inc Medications for Prurigo Nodularis Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.3.4 Pfizer Inc Main Business Overview
 - 13.3.5 Pfizer Inc Latest Developments
- 13.4 Hikma Pharmaceuticals PLC
 - 13.4.1 Hikma Pharmaceuticals PLC Company Information
 - 13.4.2 Hikma Pharmaceuticals PLC Medications for Prurigo Nodularis Product Portfolios and Specifications
 - 13.4.3 Hikma Pharmaceuticals PLC Medications for Prurigo Nodularis Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.4.4 Hikma Pharmaceuticals PLC Main Business Overview
 - 13.4.5 Hikma Pharmaceuticals PLC Latest Developments
- 13.5 Takeda Pharmaceutical Company Limited
 - 13.5.1 Takeda Pharmaceutical Company Limited Company Information
 - 13.5.2 Takeda Pharmaceutical Company Limited Medications for Prurigo Nodularis Product Portfolios and Specifications
 - 13.5.3 Takeda Pharmaceutical Company Limited Medications for Prurigo Nodularis Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.5.4 Takeda Pharmaceutical Company Limited Main Business Overview
 - 13.5.5 Takeda Pharmaceutical Company Limited Latest Developments
- 13.6 Bayer AG
 - 13.6.1 Bayer AG Company Information
 - 13.6.2 Bayer AG Medications for Prurigo Nodularis Product Portfolios and Specifications
 - 13.6.3 Bayer AG Medications for Prurigo Nodularis Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.6.4 Bayer AG Main Business Overview
 - 13.6.5 Bayer AG Latest Developments
- 13.7 Merck & Co., Inc
 - 13.7.1 Merck & Co., Inc Company Information
 - 13.7.2 Merck & Co., Inc Medications for Prurigo Nodularis Product Portfolios and Specifications
 - 13.7.3 Merck & Co., Inc Medications for Prurigo Nodularis Sales, Revenue, Price and

Gross Margin (2021-2026)

13.7.4 Merck & Co., Inc Main Business Overview

13.7.5 Merck & Co., Inc Latest Developments

13.8 Sanofi

13.8.1 Sanofi Company Information

13.8.2 Sanofi Medications for Prurigo Nodularis Product Portfolios and Specifications

13.8.3 Sanofi Medications for Prurigo Nodularis Sales, Revenue, Price and Gross

Margin (2021-2026)

13.8.4 Sanofi Main Business Overview

13.8.5 Sanofi Latest Developments

13.9 GSK plc

13.9.1 GSK plc Company Information

13.9.2 GSK plc Medications for Prurigo Nodularis Product Portfolios and Specifications

13.9.3 GSK plc Medications for Prurigo Nodularis Sales, Revenue, Price and Gross

Margin (2021-2026)

13.9.4 GSK plc Main Business Overview

13.9.5 GSK plc Latest Developments

13.10 BRISTOL-MYERS SQUIBB COMPANY

13.10.1 BRISTOL-MYERS SQUIBB COMPANY Company Information

13.10.2 BRISTOL-MYERS SQUIBB COMPANY Medications for Prurigo Nodularis Product Portfolios and Specifications

13.10.3 BRISTOL-MYERS SQUIBB COMPANY Medications for Prurigo Nodularis Sales, Revenue, Price and Gross Margin (2021-2026)

13.10.4 BRISTOL-MYERS SQUIBB COMPANY Main Business Overview

13.10.5 BRISTOL-MYERS SQUIBB COMPANY Latest Developments

13.11 GALDERMA LABORATORIES, L.P

13.11.1 GALDERMA LABORATORIES, L.P Company Information

13.11.2 GALDERMA LABORATORIES, L.P Medications for Prurigo Nodularis Product Portfolios and Specifications

13.11.3 GALDERMA LABORATORIES, L.P Medications for Prurigo Nodularis Sales, Revenue, Price and Gross Margin (2021-2026)

13.11.4 GALDERMA LABORATORIES, L.P Main Business Overview

13.11.5 GALDERMA LABORATORIES, L.P Latest Developments

13.12 Mayne Pharma Group Limited

13.12.1 Mayne Pharma Group Limited Company Information

13.12.2 Mayne Pharma Group Limited Medications for Prurigo Nodularis Product Portfolios and Specifications

13.12.3 Mayne Pharma Group Limited Medications for Prurigo Nodularis Sales, Revenue, Price and Gross Margin (2021-2026)

- 13.12.4 Mayne Pharma Group Limited Main Business Overview
- 13.12.5 Mayne Pharma Group Limited Latest Developments
- 13.13 VYNE Therapeutics Inc
 - 13.13.1 VYNE Therapeutics Inc Company Information
 - 13.13.2 VYNE Therapeutics Inc Medications for Prurigo Nodularis Product Portfolios and Specifications
 - 13.13.3 VYNE Therapeutics Inc Medications for Prurigo Nodularis Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.13.4 VYNE Therapeutics Inc Main Business Overview
 - 13.13.5 VYNE Therapeutics Inc Latest Developments
- 13.14 Trevi Therapeutics
 - 13.14.1 Trevi Therapeutics Company Information
 - 13.14.2 Trevi Therapeutics Medications for Prurigo Nodularis Product Portfolios and Specifications
 - 13.14.3 Trevi Therapeutics Medications for Prurigo Nodularis Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.14.4 Trevi Therapeutics Main Business Overview
 - 13.14.5 Trevi Therapeutics Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Medications for Prurigo Nodularis Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Medications for Prurigo Nodularis Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Antihistamines

Table 4. Major Players of Capsaicin Cream

Table 5. Major Players of Corticosteroids

Table 6. Major Players of Emollients

Table 7. Major Players of Other

Table 8. Global Medications for Prurigo Nodularis Sales by Type (2021-2026) & (K Units)

Table 9. Global Medications for Prurigo Nodularis Sales Market Share by Type (2021-2026)

Table 10. Global Medications for Prurigo Nodularis Revenue by Type (2021-2026) & (\$ million)

Table 11. Global Medications for Prurigo Nodularis Revenue Market Share by Type (2021-2026)

Table 12. Global Medications for Prurigo Nodularis Sale Price by Type (2021-2026) & (US\$/Unit)

Table 13. Global Medications for Prurigo Nodularis Sale by Application (2021-2026) & (K Units)

Table 14. Global Medications for Prurigo Nodularis Sale Market Share by Application (2021-2026)

Table 15. Global Medications for Prurigo Nodularis Revenue by Application (2021-2026) & (\$ million)

Table 16. Global Medications for Prurigo Nodularis Revenue Market Share by Application (2021-2026)

Table 17. Global Medications for Prurigo Nodularis Sale Price by Application (2021-2026) & (US\$/Unit)

Table 18. Global Medications for Prurigo Nodularis Sales by Company (2021-2026) & (K Units)

Table 19. Global Medications for Prurigo Nodularis Sales Market Share by Company (2021-2026)

Table 20. Global Medications for Prurigo Nodularis Revenue by Company (2021-2026) & (\$ millions)

Table 21. Global Medications for Prurigo Nodularis Revenue Market Share by Company (2021-2026)

Table 22. Global Medications for Prurigo Nodularis Sale Price by Company (2021-2026) & (US\$/Unit)

Table 23. Key Manufacturers Medications for Prurigo Nodularis Producing Area Distribution and Sales Area

Table 24. Players Medications for Prurigo Nodularis Products Offered

Table 25. Medications for Prurigo Nodularis Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 26. New Products and Potential Entrants

Table 27. Market M&A Activity & Strategy

Table 28. Global Medications for Prurigo Nodularis Sales by Geographic Region (2021-2026) & (K Units)

Table 29. Global Medications for Prurigo Nodularis Sales Market Share Geographic Region (2021-2026)

Table 30. Global Medications for Prurigo Nodularis Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 31. Global Medications for Prurigo Nodularis Revenue Market Share by Geographic Region (2021-2026)

Table 32. Global Medications for Prurigo Nodularis Sales by Country/Region (2021-2026) & (K Units)

Table 33. Global Medications for Prurigo Nodularis Sales Market Share by Country/Region (2021-2026)

Table 34. Global Medications for Prurigo Nodularis Revenue by Country/Region (2021-2026) & (\$ millions)

Table 35. Global Medications for Prurigo Nodularis Revenue Market Share by Country/Region (2021-2026)

Table 36. Americas Medications for Prurigo Nodularis Sales by Country (2021-2026) & (K Units)

Table 37. Americas Medications for Prurigo Nodularis Sales Market Share by Country (2021-2026)

Table 38. Americas Medications for Prurigo Nodularis Revenue by Country (2021-2026) & (\$ millions)

Table 39. Americas Medications for Prurigo Nodularis Sales by Type (2021-2026) & (K Units)

Table 40. Americas Medications for Prurigo Nodularis Sales by Application (2021-2026) & (K Units)

Table 41. APAC Medications for Prurigo Nodularis Sales by Region (2021-2026) & (K Units)

Table 42. APAC Medications for Prurigo Nodularis Sales Market Share by Region (2021-2026)

Table 43. APAC Medications for Prurigo Nodularis Revenue by Region (2021-2026) & (\$ millions)

Table 44. APAC Medications for Prurigo Nodularis Sales by Type (2021-2026) & (K Units)

Table 45. APAC Medications for Prurigo Nodularis Sales by Application (2021-2026) & (K Units)

Table 46. Europe Medications for Prurigo Nodularis Sales by Country (2021-2026) & (K Units)

Table 47. Europe Medications for Prurigo Nodularis Revenue by Country (2021-2026) & (\$ millions)

Table 48. Europe Medications for Prurigo Nodularis Sales by Type (2021-2026) & (K Units)

Table 49. Europe Medications for Prurigo Nodularis Sales by Application (2021-2026) & (K Units)

Table 50. Middle East & Africa Medications for Prurigo Nodularis Sales by Country (2021-2026) & (K Units)

Table 51. Middle East & Africa Medications for Prurigo Nodularis Revenue Market Share by Country (2021-2026)

Table 52. Middle East & Africa Medications for Prurigo Nodularis Sales by Type (2021-2026) & (K Units)

Table 53. Middle East & Africa Medications for Prurigo Nodularis Sales by Application (2021-2026) & (K Units)

Table 54. Key Market Drivers & Growth Opportunities of Medications for Prurigo Nodularis

Table 55. Key Market Challenges & Risks of Medications for Prurigo Nodularis

Table 56. Key Industry Trends of Medications for Prurigo Nodularis

Table 57. Medications for Prurigo Nodularis Raw Material

Table 58. Key Suppliers of Raw Materials

Table 59. Medications for Prurigo Nodularis Distributors List

Table 60. Medications for Prurigo Nodularis Customer List

Table 61. Global Medications for Prurigo Nodularis Sales Forecast by Region (2027-2032) & (K Units)

Table 62. Global Medications for Prurigo Nodularis Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 63. Americas Medications for Prurigo Nodularis Sales Forecast by Country (2027-2032) & (K Units)

Table 64. Americas Medications for Prurigo Nodularis Annual Revenue Forecast by

Country (2027-2032) & (\$ millions)

Table 65. APAC Medications for Prurigo Nodularis Sales Forecast by Region (2027-2032) & (K Units)

Table 66. APAC Medications for Prurigo Nodularis Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 67. Europe Medications for Prurigo Nodularis Sales Forecast by Country (2027-2032) & (K Units)

Table 68. Europe Medications for Prurigo Nodularis Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 69. Middle East & Africa Medications for Prurigo Nodularis Sales Forecast by Country (2027-2032) & (K Units)

Table 70. Middle East & Africa Medications for Prurigo Nodularis Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 71. Global Medications for Prurigo Nodularis Sales Forecast by Type (2027-2032) & (K Units)

Table 72. Global Medications for Prurigo Nodularis Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 73. Global Medications for Prurigo Nodularis Sales Forecast by Application (2027-2032) & (K Units)

Table 74. Global Medications for Prurigo Nodularis Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 75. Johnson & Johnson Services, Inc Basic Information, Medications for Prurigo Nodularis Manufacturing Base, Sales Area and Its Competitors

Table 76. Johnson & Johnson Services, Inc Medications for Prurigo Nodularis Product Portfolios and Specifications

Table 77. Johnson & Johnson Services, Inc Medications for Prurigo Nodularis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 78. Johnson & Johnson Services, Inc Main Business

Table 79. Johnson & Johnson Services, Inc Latest Developments

Table 80. Teva Pharmaceutical Industries Ltd Basic Information, Medications for Prurigo Nodularis Manufacturing Base, Sales Area and Its Competitors

Table 81. Teva Pharmaceutical Industries Ltd Medications for Prurigo Nodularis Product Portfolios and Specifications

Table 82. Teva Pharmaceutical Industries Ltd Medications for Prurigo Nodularis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 83. Teva Pharmaceutical Industries Ltd Main Business

Table 84. Teva Pharmaceutical Industries Ltd Latest Developments

Table 85. Pfizer Inc Basic Information, Medications for Prurigo Nodularis Manufacturing Base, Sales Area and Its Competitors

- Table 86. Pfizer Inc Medications for Prurigo Nodularis Product Portfolios and Specifications
- Table 87. Pfizer Inc Medications for Prurigo Nodularis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 88. Pfizer Inc Main Business
- Table 89. Pfizer Inc Latest Developments
- Table 90. Hikma Pharmaceuticals PLC Basic Information, Medications for Prurigo Nodularis Manufacturing Base, Sales Area and Its Competitors
- Table 91. Hikma Pharmaceuticals PLC Medications for Prurigo Nodularis Product Portfolios and Specifications
- Table 92. Hikma Pharmaceuticals PLC Medications for Prurigo Nodularis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 93. Hikma Pharmaceuticals PLC Main Business
- Table 94. Hikma Pharmaceuticals PLC Latest Developments
- Table 95. Takeda Pharmaceutical Company Limited Basic Information, Medications for Prurigo Nodularis Manufacturing Base, Sales Area and Its Competitors
- Table 96. Takeda Pharmaceutical Company Limited Medications for Prurigo Nodularis Product Portfolios and Specifications
- Table 97. Takeda Pharmaceutical Company Limited Medications for Prurigo Nodularis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 98. Takeda Pharmaceutical Company Limited Main Business
- Table 99. Takeda Pharmaceutical Company Limited Latest Developments
- Table 100. Bayer AG Basic Information, Medications for Prurigo Nodularis Manufacturing Base, Sales Area and Its Competitors
- Table 101. Bayer AG Medications for Prurigo Nodularis Product Portfolios and Specifications
- Table 102. Bayer AG Medications for Prurigo Nodularis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 103. Bayer AG Main Business
- Table 104. Bayer AG Latest Developments
- Table 105. Merck & Co., Inc Basic Information, Medications for Prurigo Nodularis Manufacturing Base, Sales Area and Its Competitors
- Table 106. Merck & Co., Inc Medications for Prurigo Nodularis Product Portfolios and Specifications
- Table 107. Merck & Co., Inc Medications for Prurigo Nodularis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 108. Merck & Co., Inc Main Business
- Table 109. Merck & Co., Inc Latest Developments
- Table 110. Sanofi Basic Information, Medications for Prurigo Nodularis Manufacturing

Base, Sales Area and Its Competitors

Table 111. Sanofi Medications for Prurigo Nodularis Product Portfolios and Specifications

Table 112. Sanofi Medications for Prurigo Nodularis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 113. Sanofi Main Business

Table 114. Sanofi Latest Developments

Table 115. GSK plc Basic Information, Medications for Prurigo Nodularis Manufacturing Base, Sales Area and Its Competitors

Table 116. GSK plc Medications for Prurigo Nodularis Product Portfolios and Specifications

Table 117. GSK plc Medications for Prurigo Nodularis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 118. GSK plc Main Business

Table 119. GSK plc Latest Developments

Table 120. BRISTOL-MYERS SQUIBB COMPANY Basic Information, Medications for Prurigo Nodularis Manufacturing Base, Sales Area and Its Competitors

Table 121. BRISTOL-MYERS SQUIBB COMPANY Medications for Prurigo Nodularis Product Portfolios and Specifications

Table 122. BRISTOL-MYERS SQUIBB COMPANY Medications for Prurigo Nodularis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 123. BRISTOL-MYERS SQUIBB COMPANY Main Business

Table 124. BRISTOL-MYERS SQUIBB COMPANY Latest Developments

Table 125. GALDERMA LABORATORIES, L.P Basic Information, Medications for Prurigo Nodularis Manufacturing Base, Sales Area and Its Competitors

Table 126. GALDERMA LABORATORIES, L.P Medications for Prurigo Nodularis Product Portfolios and Specifications

Table 127. GALDERMA LABORATORIES, L.P Medications for Prurigo Nodularis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 128. GALDERMA LABORATORIES, L.P Main Business

Table 129. GALDERMA LABORATORIES, L.P Latest Developments

Table 130. Mayne Pharma Group Limited Basic Information, Medications for Prurigo Nodularis Manufacturing Base, Sales Area and Its Competitors

Table 131. Mayne Pharma Group Limited Medications for Prurigo Nodularis Product Portfolios and Specifications

Table 132. Mayne Pharma Group Limited Medications for Prurigo Nodularis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 133. Mayne Pharma Group Limited Main Business

Table 134. Mayne Pharma Group Limited Latest Developments

Table 135. VYNE Therapeutics Inc Basic Information, Medications for Prurigo Nodularis Manufacturing Base, Sales Area and Its Competitors

Table 136. VYNE Therapeutics Inc Medications for Prurigo Nodularis Product Portfolios and Specifications

Table 137. VYNE Therapeutics Inc Medications for Prurigo Nodularis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 138. VYNE Therapeutics Inc Main Business

Table 139. VYNE Therapeutics Inc Latest Developments

Table 140. Trevi Therapeutics Basic Information, Medications for Prurigo Nodularis Manufacturing Base, Sales Area and Its Competitors

Table 141. Trevi Therapeutics Medications for Prurigo Nodularis Product Portfolios and Specifications

Table 142. Trevi Therapeutics Medications for Prurigo Nodularis Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 143. Trevi Therapeutics Main Business

Table 144. Trevi Therapeutics Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Medications for Prurigo Nodularis
- Figure 2. Medications for Prurigo Nodularis Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Medications for Prurigo Nodularis Sales Growth Rate 2021-2032 (K Units)
- Figure 7. Global Medications for Prurigo Nodularis Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Medications for Prurigo Nodularis Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Medications for Prurigo Nodularis Sales Market Share by Country/Region (2025)
- Figure 10. Medications for Prurigo Nodularis Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Antihistamines
- Figure 12. Product Picture of Capsaicin Cream
- Figure 13. Product Picture of Corticosteroids
- Figure 14. Product Picture of Emollients
- Figure 15. Product Picture of Other
- Figure 16. Global Medications for Prurigo Nodularis Sales Market Share by Type in 2026
- Figure 17. Global Medications for Prurigo Nodularis Revenue Market Share by Type (2021-2026)
- Figure 18. Medications for Prurigo Nodularis Consumed in Hospitals
- Figure 19. Global Medications for Prurigo Nodularis Market: Hospitals (2021-2026) & (K Units)
- Figure 20. Medications for Prurigo Nodularis Consumed in Specialty Clinics
- Figure 21. Global Medications for Prurigo Nodularis Market: Specialty Clinics (2021-2026) & (K Units)
- Figure 22. Medications for Prurigo Nodularis Consumed in Homecare
- Figure 23. Global Medications for Prurigo Nodularis Market: Homecare (2021-2026) & (K Units)
- Figure 24. Medications for Prurigo Nodularis Consumed in Other
- Figure 25. Global Medications for Prurigo Nodularis Market: Other (2021-2026) & (K

Units)

Figure 26. Global Medications for Prurigo Nodularis Sale Market Share by Application (2025)

Figure 27. Global Medications for Prurigo Nodularis Revenue Market Share by Application in 2026

Figure 28. Medications for Prurigo Nodularis Sales by Company in 2026 (K Units)

Figure 29. Global Medications for Prurigo Nodularis Sales Market Share by Company in 2026

Figure 30. Medications for Prurigo Nodularis Revenue by Company in 2026 (\$ millions)

Figure 31. Global Medications for Prurigo Nodularis Revenue Market Share by Company in 2026

Figure 32. Global Medications for Prurigo Nodularis Sales Market Share by Geographic Region (2021-2026)

Figure 33. Global Medications for Prurigo Nodularis Revenue Market Share by Geographic Region in 2026

Figure 34. Americas Medications for Prurigo Nodularis Sales 2021-2026 (K Units)

Figure 35. Americas Medications for Prurigo Nodularis Revenue 2021-2026 (\$ millions)

Figure 36. APAC Medications for Prurigo Nodularis Sales 2021-2026 (K Units)

Figure 37. APAC Medications for Prurigo Nodularis Revenue 2021-2026 (\$ millions)

Figure 38. Europe Medications for Prurigo Nodularis Sales 2021-2026 (K Units)

Figure 39. Europe Medications for Prurigo Nodularis Revenue 2021-2026 (\$ millions)

Figure 40. Middle East & Africa Medications for Prurigo Nodularis Sales 2021-2026 (K Units)

Figure 41. Middle East & Africa Medications for Prurigo Nodularis Revenue 2021-2026 (\$ millions)

Figure 42. Americas Medications for Prurigo Nodularis Sales Market Share by Country in 2026

Figure 43. Americas Medications for Prurigo Nodularis Revenue Market Share by Country (2021-2026)

Figure 44. Americas Medications for Prurigo Nodularis Sales Market Share by Type (2021-2026)

Figure 45. Americas Medications for Prurigo Nodularis Sales Market Share by Application (2021-2026)

Figure 46. United States Medications for Prurigo Nodularis Revenue Growth 2021-2026 (\$ millions)

Figure 47. Canada Medications for Prurigo Nodularis Revenue Growth 2021-2026 (\$ millions)

Figure 48. Mexico Medications for Prurigo Nodularis Revenue Growth 2021-2026 (\$ millions)

Figure 49. Brazil Medications for Prurigo Nodularis Revenue Growth 2021-2026 (\$ millions)

Figure 50. APAC Medications for Prurigo Nodularis Sales Market Share by Region in 2026

Figure 51. APAC Medications for Prurigo Nodularis Revenue Market Share by Region (2021-2026)

Figure 52. APAC Medications for Prurigo Nodularis Sales Market Share by Type (2021-2026)

Figure 53. APAC Medications for Prurigo Nodularis Sales Market Share by Application (2021-2026)

Figure 54. China Medications for Prurigo Nodularis Revenue Growth 2021-2026 (\$ millions)

Figure 55. Japan Medications for Prurigo Nodularis Revenue Growth 2021-2026 (\$ millions)

Figure 56. South Korea Medications for Prurigo Nodularis Revenue Growth 2021-2026 (\$ millions)

Figure 57. Southeast Asia Medications for Prurigo Nodularis Revenue Growth 2021-2026 (\$ millions)

Figure 58. India Medications for Prurigo Nodularis Revenue Growth 2021-2026 (\$ millions)

Figure 59. Australia Medications for Prurigo Nodularis Revenue Growth 2021-2026 (\$ millions)

Figure 60. China Taiwan Medications for Prurigo Nodularis Revenue Growth 2021-2026 (\$ millions)

Figure 61. Europe Medications for Prurigo Nodularis Sales Market Share by Country in 2026

Figure 62. Europe Medications for Prurigo Nodularis Revenue Market Share by Country (2021-2026)

Figure 63. Europe Medications for Prurigo Nodularis Sales Market Share by Type (2021-2026)

Figure 64. Europe Medications for Prurigo Nodularis Sales Market Share by Application (2021-2026)

Figure 65. Germany Medications for Prurigo Nodularis Revenue Growth 2021-2026 (\$ millions)

Figure 66. France Medications for Prurigo Nodularis Revenue Growth 2021-2026 (\$ millions)

Figure 67. UK Medications for Prurigo Nodularis Revenue Growth 2021-2026 (\$ millions)

Figure 68. Italy Medications for Prurigo Nodularis Revenue Growth 2021-2026 (\$

millions)

Figure 69. Russia Medications for Prurigo Nodularis Revenue Growth 2021-2026 (\$ millions)

Figure 70. Middle East & Africa Medications for Prurigo Nodularis Sales Market Share by Country (2021-2026)

Figure 71. Middle East & Africa Medications for Prurigo Nodularis Sales Market Share by Type (2021-2026)

Figure 72. Middle East & Africa Medications for Prurigo Nodularis Sales Market Share by Application (2021-2026)

Figure 73. Egypt Medications for Prurigo Nodularis Revenue Growth 2021-2026 (\$ millions)

Figure 74. South Africa Medications for Prurigo Nodularis Revenue Growth 2021-2026 (\$ millions)

Figure 75. Israel Medications for Prurigo Nodularis Revenue Growth 2021-2026 (\$ millions)

Figure 76. Turkey Medications for Prurigo Nodularis Revenue Growth 2021-2026 (\$ millions)

Figure 77. GCC Countries Medications for Prurigo Nodularis Revenue Growth 2021-2026 (\$ millions)

Figure 78. Manufacturing Cost Structure Analysis of Medications for Prurigo Nodularis in 2026

Figure 79. Manufacturing Process Analysis of Medications for Prurigo Nodularis

Figure 80. Industry Chain Structure of Medications for Prurigo Nodularis

Figure 81. Channels of Distribution

Figure 82. Global Medications for Prurigo Nodularis Sales Market Forecast by Region (2027-2032)

Figure 83. Global Medications for Prurigo Nodularis Revenue Market Share Forecast by Region (2027-2032)

Figure 84. Global Medications for Prurigo Nodularis Sales Market Share Forecast by Type (2027-2032)

Figure 85. Global Medications for Prurigo Nodularis Revenue Market Share Forecast by Type (2027-2032)

Figure 86. Global Medications for Prurigo Nodularis Sales Market Share Forecast by Application (2027-2032)

Figure 87. Global Medications for Prurigo Nodularis Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Medications for Prurigo Nodularis Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G31BFE8655AFEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G31BFE8655AFEN.html>